Characterization of Virologic Rebound Following Nirmatrelvir-Ritonavir Treatment for Coronavirus Disease 2019 (COVID-19). (15th July 2022)

• Record Type: Journal Article
• Authors: Boucau, Julie; Uddin, Rockib; Marino, Caitlin; Regan, James; Flynn, James P; Choudhary, Manish C; Chen, Geoffrey; Stuckwisch, Ashley M; Mathews, Josh; Liew, May Y; Singh, Arshdeep; Reynolds, Zahra; Iyer, Surabhi L; Chamberlin, Grace C; Vyas, Tammy D; Vyas, Jatin M; Turbett, Sarah E; Li, Jonathan Z; Lemieux, Jacob E; Barczak, Amy K; Siedner, Mark J
• Is Part Of: Clinical infectious diseases. Volume 76:Number 3(2023)
• Page Start: e526
• Page End: e529
• Publication Date: 2022-07-15
• Subjects: COVID-19 -- therapeutics -- anti-virals -- nirmatrelvir-ritonavir -- virology; Communicable diseases -- Periodicals; 616.905
• DOI: 10.1093/cid/ciac512
• Languages: English
• ISSNs: 1058-4838

Abstract

Abstract: We enrolled 7 individuals with recurrent symptoms or antigen test conversion following nirmatrelvir-ritonavir treatment. High viral loads (median 6.1 log10 copies/mL) were detected after rebound for a median of 17 days after initial diagnosis. Three had culturable virus for up to 16 days after initial diagnosis. No known resistance-associated mutations were identified.